Zobrazeno 1 - 10 of 13 pro vyhledávání: '"Galabina Bozhanova"'
1
Akademický článek
Combination of oncolytic Maraba virus with immune checkpoint blockade overcomes therapy resistance in an immunologically cold model of advanced melanoma with dysfunctional T-cell receptor signalling
Autor: Victoria Jennings, Alan Melcher, Fiona Errington-Mais, Victoria Roulstone, Kevin J Harrington, Galabina Bozhanova, Shane Foo, Martin McLaughlin, Malin Pedersen, John Bell, Pablo Nenclares, Joan Kyula, Lizzie Appleton, Edward Armstrong, Masahiro Ono, Matthew K L Chiu, Anton Patrikeev, Nitya Mohan, Julia Hoebart, Emmanuel Patin
Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 12, Iss 7 (2024)
Background Over the past decade, cancer immunotherapies have revolutionized the treatment of melanoma; however, responses vary across patient populations. Recently, baseline tumor size has been identified as an independent prognostic factor for overa
Externí odkaz: https://doaj.org/article/2760efb5528c442eb6992610bc801ce3
Zobrazit plný text záznamu
2
Akademický článek
CD4 T cell dynamics shape the immune response to combination oncolytic herpes virus and BRAF inhibitor therapy for melanoma
Autor: Victoria Jennings, Kevin Harrington, Hardev Pandha, Alan Melcher, Adel Samson, Fiona Errington-Mais, Victoria Roulstone, Eva Crespo-Rodriguez, Galabina Bozhanova, Shane Foo, Emmanuel C Patin, Martin McLaughlin, Malin Pedersen, Richard Vile, Joan Kyula, Jehanne Hassan, Lizzie Appleton, Charleen ML Chan Wah Hak, Gabby Baker, Edward Armstrong, Matthew Chiu, Masahiro Ono
Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 10, Iss 3 (2022)
Background Combination herpes simplex virus (HSV) oncolytic virotherapy and BRAF inhibitors (BRAFi) represent promising immunogenic treatments for BRAF mutant melanoma, but an improved understanding of the immunobiology of combinations is needed to i
Externí odkaz: https://doaj.org/article/316204113b0e4019ac28423a26ae7cf2
Zobrazit plný text záznamu
3
Akademický článek
Harnessing radiotherapy-induced NK-cell activity by combining DNA damage–response inhibition and immune checkpoint blockade
Autor: Simon Smith, Hormas Ghadially, Kevin J Harrington, Alan A Melcher, Isla Leslie, Eva Crespo-Rodriguez, Galabina Bozhanova, Emmanuel C Patin, Harriet Whittock, Martin McLaughlin, Malin Pedersen, James Harper, Pablo Nenclares, Heba Soliman, Magnus T Dillon, Lorna Grove, Davina Northcote, Holly Baldock, Gabriella Baker, Joan Kyula, Jeane Guevara
Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 10, Iss 3 (2022)
Background Despite therapeutic gains from immune checkpoint inhibitors (ICI) in many tumor types, new strategies are needed to extend treatment benefits, especially in patients failing to mount effective antitumor T-cell responses. Radiation and drug
Externí odkaz: https://doaj.org/article/352213c6f2484a688ddb7a66accbad6a
Zobrazit plný text záznamu
4
Akademický článek
Combining BRAF inhibition with oncolytic herpes simplex virus enhances the immune-mediated antitumor therapy of BRAF-mutant thyroid cancer
Autor: Khin Thway, Kevin J Harrington, Alan A Melcher, Eva Crespo-Rodriguez, Katharina Bergerhoff, Galabina Bozhanova, Shane Foo, Emmanuel C Patin, Harriet Whittock, Richard Buus, Syed Haider, Gareth Muirhead, Kate Newbold, Robert S Coffin, Richard G Vile, Dae Kim, Martin McLaughlin, Malin Pedersen
Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Background The aggressive clinical behavior of poorly differentiated and anaplastic thyroid cancers (PDTC and ATC) has proven challenging to treat, and survival beyond a few months from diagnosis is rare. Although 30%–60% of these tumors contain mu
Externí odkaz: https://doaj.org/article/ad0aeec772af4e7bb8cf7fe2244c748e
Zobrazit plný text záznamu
7
Combination therapy with oncolytic viruses and immune checkpoint inhibitors
Autor: Joan N. Kyula, Gabriella Baker, David Mansfield, Matthew Chiu, Anna Wilkins, Kevin J. Harrington, Eva Crespo-Rodriguez, Edward Armstrong, Alan Melcher, Martin McLaughlin, Fiona McDonald, Vicki Jennings, Victoria Roulstone, Shane Foo, Malin Pedersen, Galabina Bozhanova, Lorna Grove, Emmanuel C Patin
Publikováno v: Expert Opinion on Biological Therapy. 20:635-652
Introduction: Immune checkpoint inhibitors (ICI) have dramatically improved the outcome for cancer patients across multiple tumor types. However the response rates to ICI monotherapy remain relativ...
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fcfd52b4d85e7d295f7c6a3464737c06
https://doi.org/10.1080/14712598.2020.1729351
Zobrazit plný text záznamu
8
Harnessing radiotherapy-induced NK-cell activity by combining DNA damage–response inhibition and immune checkpoint blockade
Autor: Emmanuel C Patin, Magnus T Dillon, Pablo Nenclares, Lorna Grove, Heba Soliman, Isla Leslie, Davina Northcote, Galabina Bozhanova, Eva Crespo-Rodriguez, Holly Baldock, Harriet Whittock, Gabriella Baker, Joan Kyula, Jeane Guevara, Alan A Melcher, James Harper, Hormas Ghadially, Simon Smith, Malin Pedersen, Martin McLaughlin, Kevin J Harrington
Publikováno v: Journal for ImmunoTherapy of Cancer. 10:e004306
BackgroundDespite therapeutic gains from immune checkpoint inhibitors (ICI) in many tumor types, new strategies are needed to extend treatment benefits, especially in patients failing to mount effective antitumor T-cell responses. Radiation and drug
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::314084510b1da386dd08c7bf877e80f3
https://doi.org/10.1136/jitc-2021-004306
Zobrazit plný text záznamu
10
Combining BRAF inhibition with oncolytic herpes simplex virus enhances the immune-mediated antitumor therapy of BRAF-mutant thyroid cancer
Autor: Syed Haider, Robert S. Coffin, Eva Crespo-Rodriguez, Khin Thway, Richard Buus, Alan Melcher, Richard G. Vile, Harriet Whittock, Emmanuel C Patin, Galabina Bozhanova, Kate Newbold, Dae Kim, Katharina F. Bergerhoff, Malin Pedersen, Gareth Muirhead, Martin McLaughlin, Shane Foo, Kevin J. Harrington
Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Journal for Immunotherapy of Cancer
BackgroundThe aggressive clinical behavior of poorly differentiated and anaplastic thyroid cancers (PDTC and ATC) has proven challenging to treat, and survival beyond a few months from diagnosis is rare. Although 30%–60% of these tumors contain mut
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e029ae20d8e2e59ec06a021b2a3ee96
https://jitc.bmj.com/content/8/2/e000698.full
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje